Immunogenicity and Protective Efficacy of a Dual Subunit Vaccine Against Respiratory Syncytial Virus and Influenza Virus.
- Author:
Min Hee PARK
1
;
Jun CHANG
Author Information
- Publication Type:Original Article
- Keywords: Respiratory syncytial virus; Influenza virus; G glycoprotein; Hemagglutinin; Dual vaccine; Intranasal immunization; Protective immunity
- MeSH: Animals; Cholera Toxin; Chorionic Gonadotropin, beta Subunit, Human; Chromatography, Affinity; GTP-Binding Proteins; Head; Hemagglutinins; Immunization; Immunoglobulin A; Immunoglobulin G; Influenza, Human; Lung; Mice; Orthomyxoviridae; Peptide Fragments; Respiratory Syncytial Viruses; Respiratory Tract Diseases; Vaccination; Vaccines
- From:Immune Network 2012;12(6):261-268
- CountryRepublic of Korea
- Language:English
- Abstract: Respiratory syncytial virus (RSV) and influenza virus are the most significant pathogens causing respiratory tract diseases. Composite vaccines are useful in reducing the number of vaccination and confer protection against multiple infectious agents. In this study, we generated fusion of RSV G protein core fragment (amino acid residues 131 to 230) and influenza HA1 globular head domain (amino acid residues 62 to 284) as a dual vaccine candidate. This fusion protein, Gcf-HA1, was bacterially expressed, purified by metal resin affinity chromatography, and refolded in PBS. BALB/c mice were intranasally immunized with Gcf-HA1 in combination with a mucosal adjuvant, cholera toxin (CT). Both serum IgG and mucosal IgA responses specific to Gcf and HA1 were significantly increased in Gcf-HA1/CT-vaccinated mice. To determine the protective efficacy of Gcf-HA1/CT vaccine, immunized mice were challenged with RSV (A2 strain) or influenza virus (A/PR/8/34). Neither detectable viral replication nor pathology was observed in the lungs of the immune mice. These results demonstrate that immunity induced by intranasal Gcf-HA1/CT immunization confers complete protection against both RSV and homologous influenza virus infection, suggesting our Gcf-HA1 vaccine candidate could be further developed as a dual subunit vaccine against RSV and influenza virus.
